---
title: "Barrington Reaffirms Their Buy Rating on Grand Canyon Education (LOPE)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284910896.md"
description: "Barrington analyst Alexander Paris has reaffirmed a Buy rating on Grand Canyon Education (LOPE) with a price target of $230.00. Paris, who specializes in the Consumer Defensive sector, has an average return of 19.5% and a 66.07% success rate on his stock recommendations. The analyst consensus for Grand Canyon Education is a Moderate Buy, also with a price target of $230.00."
datetime: "2026-05-01T13:49:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284910896.md)
  - [en](https://longbridge.com/en/news/284910896.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284910896.md)
---

# Barrington Reaffirms Their Buy Rating on Grand Canyon Education (LOPE)

Barrington analyst Alexander Paris reiterated a Buy rating on Grand Canyon Education today and set a price target of $230.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Paris covers the Consumer Defensive sector, focusing on stocks such as Perdoceo Education, Grand Canyon Education, and Stride. According to TipRanks, Paris has an average return of 19.5% and a 66.07% success rate on recommended stocks.

Grand Canyon Education has an analyst consensus of Moderate Buy, with a price target consensus of $230.00.

### Related Stocks

- [LOPE.US](https://longbridge.com/en/quote/LOPE.US.md)
- [PRDO.US](https://longbridge.com/en/quote/PRDO.US.md)
- [LRN.US](https://longbridge.com/en/quote/LRN.US.md)

## Related News & Research

- [Grand Canyon Education, Inc. $LOPE Shares Acquired by American Century Companies Inc.](https://longbridge.com/en/news/278204946.md)
- [ABN Amro Investment Solutions Sells 6,243 Shares of Grand Canyon Education, Inc. $LOPE](https://longbridge.com/en/news/275999138.md)
- [LifeSci Capital Sticks to Their Buy Rating for Olema Pharmaceuticals (OLMA)](https://longbridge.com/en/news/286679129.md)
- [Analyst Reiterates Buy on Dermata, Keeps 12-Month Price Target Unchanged at $4](https://longbridge.com/en/news/286958909.md)
- [ZAWYA: Mazad hosts Lamea introductory workshop for employees](https://longbridge.com/en/news/286674396.md)